• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Cerenis Therapeutics

edit

Cerenis Therapeutics is a multinational biotechnology company dedicated to the discovery, development and commercialization of novel HDL therapies for the treatment of cardiovascular and metabolic diseases.

Recent Milestones

edit

• 
  Cerenis Therapeutics received $14M (€10M) in Series C funding. (10/21/10)
  Posted 10/22/10 at 7:07pm via cerenis.com
• 
  Cerenis Therapeutics received $13.8M (€10.7M) in Grant funding. (7/26/10)
  Posted 7/26/10 at 6:18pm via cerenis.com
• 
  Cerenis Therapeutics received $51.7M (€40M) in Series C funding. (7/26/10)
  Posted 7/26/10 at 6:18pm via cerenis.com
• 
  Cerenis Therapeutics added Jean-Louis Dasseux as President and CEO.
  Posted 7/26/10 at 6:18pm
• 
  Cerenis Therapeutics added William Brinkerhoff as COO.
  Posted 7/26/10 at 6:18pm

Videos

Screenshots

edit

Sources

1. Cerenis Therapeutics and Novasep awarded EUR 10.7 million funding from the French Government for the development CER-001, an HDL mimetic (cerenis.com) [edit]
2. Cerenis Therapeutics raises EUR 40 million in series C financing (cerenis.com) [edit]
3. Cerenis Therapeutics raises additional €10 million to close €50 million Series C financing (cerenis.com) [edit]